TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
Karo Pharma AS
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
714,242
|
692,039
|
640,717 |
| Financial expenses |
4,531
|
16,193
|
9,255 |
| Earnings before taxes |
187,512
|
161,427
|
126,201 |
| Total assets |
502,230
|
449,565
|
381,062 |
| Current assets |
465,604
|
410,871
|
338,348 |
| Current liabilities |
299,445
|
298,527
|
232,775 |
| Equity capital |
202,785
|
151,038
|
148,287 |
| - share capital |
6,798
|
6,798
|
6,798 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
40.4%
|
33.6%
|
38.9% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
26.3%
|
23.3%
|
19.7% |
| Return on assets (ROA) |
38.2%
|
39.5%
|
35.5% |
| Current ratio |
155.5%
|
137.6%
|
145.4% |
| Return on equity (ROE) |
92.5%
|
106.9%
|
85.1% |
| Change turnover |
22,203
|
51,322
|
136,462 |
| Change turnover % |
3%
|
8%
|
27% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.